TCG Lifesciences has announced a strategic collaboration with ENDO Pharmaceuticals to discover novel small molecule drug candidates for the treatment of pain. Working closely with ENDO scientists the collaboration will focus on an integrated approach involving medicinal chemistry, biology and animal pharmacology capabilities of Chembiotek. ENDO will have full ownership of the compounds developed under the collaboration with exclusive worldwide rights, and will fund all subsequent drug development and commercialization activities. ENDO will provide research funding and pay success based discovery milestones payments to TCG Lifesciences.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.